[ad_1]
A study gives hope: According to data from a phase I study published in the New England Journal of Medicine (NEJM), Moderna’s corona vaccine is showing an effect. And in the long term. The antibody production caused by the American company’s vaccine is clearly detectable in the blood for several months.
The result could indicate that the Moderna vaccine offers protection against Covid-19 for a longer period of time. But that is not a test.
The vaccine, called mRNA-1273, produced high levels of binding and neutralizing antibodies, which, as expected, decreased slightly over time, but still increased in all participants three months after the booster dose, ”the experts write. headed by Alicia T. Institute of Infectious Diseases.
Experts in vaccination schedule: “First people at risk, then health workers”(00:49)
Modern brims with optimism
“These data keep us optimistic that the high level of efficacy recently demonstrated by mRNA-1273 in preventing Covid-19 disease will be permanent,” said Moderna’s Tal Zaks, according to a press release.
At the same time, Moderna renewed its expectation that 20 million doses of vaccines should be available in the US before the end of the year. Production of 100 to 125 million doses of Moderna vaccine is expected during the first three months of next year.
Of these, 15 to 25 million should be available outside the US Overall, the group expects to be able to manufacture up to 1 billion doses of vaccines worldwide by 2021. To have complete immune protection, each vaccinated person must receive two doses.
94.1 percent effectiveness: Moderna requests approval of the corona vaccine in Europe(00:33)
No serious side effects
As the medical journal continues, antibodies to Sars-CoV-2 were found in the blood of the 34 subjects in the phase I study 90 days after the second dose of vaccination. Therefore, this result was observed in all age groups, including participants older than 71 years. The test people did not experience serious side effects.
The company announced in late November, based on its phase III study, that its vaccine was 94.1 percent effective. Moderna has applied for approval of its vaccine in the US and with the European Medicines Agency Ema. (SDA)
Corona vaccine application in the US: Will the first injections be available next week?(00:50)
